Source: Annual Congress 2013 –Alpha-1 antitrypsin deficiency and the lung: celebrating the 50th anniversary of its first description
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. A. Stockley (Birmingham, United Kingdom). AATD: Implications for our understanding of usual COPD. Annual Congress 2013 –Alpha-1 antitrypsin deficiency and the lung: celebrating the 50th anniversary of its first description

Member's Comments

No comment yet.

Related content which might interest you: Physician perspectives: monitoring severe AATD and optimising treatment Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Mechanisms of COPD exacerbations - molecular perspectives and pathophysiology Source: ERS Satellites 2021 Year: 2021 Improving our patients' understanding of their asthma Source: International Congress 2019 – Medical education Year: 2019 Physician perspectives: barriers to diagnosing and treating severe AATD Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Understanding patients' needs: the impact of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 69s Year: 2003 Clinical implications of the new concepts regarding COPD pathophysiology Source: Annual Congress 2008 - New insights into COPD pathophysiology Year: 2008 Potential usefulness of phenotyping in asthma and COPD Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 Clustering asthma and COPD provides new evidence for both “British” and “Dutch” hypotheses of COPD development Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Defining asthma and COPD: differential diagnosis Source: International Congress 2018 – PG1 Asthma and chronic obstructive pulmonary disease Year: 2018 Challenges in COPD exacerbations and future research and unknowns Source: Annual Congress 2013 –Recommendations from the ERS/ATS Guideline on COPD Exacerbation Prevention Year: 2013 Linking phenotypes to personalised treatments in asthma and COPD Source: Virtual Congress 2021 – Precision medicine in asthma and COPD Year: 2021 Towards an understanding of PREMS and PROMS in COPD Source: Breathe 2013; 10: 358-364 Year: 2013 Is there a need for pharmacoepidemiology in asthma and COPD? Source: Annual Congress 2004 - Pharmacoepidemiology of obstructive lung disease: beyond clinical trials Year: 2004 Rethinking COPD Exacerbations: a global patient perspective Source: Virtual Congress 2021 – Innovations in nurse-led interventions in respiratory diseases Year: 2021 Effectiveness of a comprehensive management program of fragile COPD patients Source: International Congress 2014 – Phenotyping and monitoring asthma and COPD Year: 2014 COPD: GOLD 2011 and implications for clinical practice Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Distribution of COPD phenotypes according to the Spanish COPD guidelines in clinical practice Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Effect of spirometry on COPD management in primary care: where are the studies that we really need? Source: Eur Respir J 2007; 29: 820 Year: 2007 Reversibility at pulmonary function tests: can it have implications in patients with COPD? Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021